Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ages 6 up to 18~* ADHD diagnosis with ADHD Rating Scale - 4th Edition scores ≥ 90th percentile~* In need of treatment for ADHD and able to have 2-day washout from previous medication~* Females of child-bearing potential not pregnant and practice birth control~* Subject and parent/guardian willing to comply with protocol~* Signed consent and assent~Exclusion Criteria:~* Estimated Full Scale intellectual level below 80 using Wechsler Abbreviated Scale of Intelligence (WASI)~* Current primary psychiatric diagnosis of other listed disorders~* Chronic medical illnesses: seizure, hypertension, thyroid disease, cardiac, family history of sudden death, glaucoma~* Use of psychotropic central nervous system (CNS) meds having effect exceeding 14 days from screening~* Planned use of prohibited drugs~* Is pregnant or breast-feeding~* Significant ECG or laboratory abnormalities~* Experimental drug or medical device within 30 days prior to screening~* Hypersensitivity to methylphenidate~* Inability or unwillingness to comply with protocol~* Well controlled on current ADHD treatment~* Inability to take oral capsules

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 10 mg (Type: ACTIVE_COMPARATOR): Biphentin Methylphenidate Hydrochloride Extended Release Capsules 10 mg
- 15 mg (Type: ACTIVE_COMPARATOR): Biphentin Methylphenidate Hydrochloride Extended Release Capsules 15 mg
- 20 mg (Type: ACTIVE_COMPARATOR): Biphentin Methylphenidate Hydrochloride Extended Release Capsules 20 mg
- 40 mg (Type: ACTIVE_COMPARATOR): Biphentin Methylphenidate Hydrochloride Extended Release Capsules 40 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules
- Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg) (Type: EXPERIMENTAL): Biphentin Methylphenidate Hydrochloride Extended Release Capsules (10, 15, 20, 40, 50 or 60 mg) - Open Label Phase

Based on this trial design, predict the completion outcome and termination type (if applicable).